Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Journal for Immunotherapy of Cancer
|
April 19, 2020
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
Coya Tapia, Phyu P Aung, Sinchita Roy-Chowdhuri, et al.
Nature Communications
|
March 30, 2019
Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor
Santanu Adhikary, Deepavali Chakravarti, Christopher Terranova, et al.
Journal of Clinical Pathology
|
August 3, 2006
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer
Khawla Al-Kuraya, Hedvika Novotny, Prashant Bavi, et al.
Scientific Reports
|
January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
Seyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 21, 2011
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time
Eric A Ariazi, Heather E Cunliffe, Joan S Lewis-Wambi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2017
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Kurt W Evans, Erkan Yuca, Argun Akcakanat, et al.
Breast Cancer Research : BCR
|
March 5, 2021
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
Seyed Pairawan, Ming Zhao, Erkan Yuca, et al.
Plos One
|
June 5, 2012
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
Zsuzsanna Varga, Joachim Diebold, Corina Dommann-Scherrer, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
JCO Precision Oncology
|
July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast Cancer
Funda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Journal for Immunotherapy of Cancer
|
April 19, 2020
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
Coya Tapia, Phyu P Aung, Sinchita Roy-Chowdhuri, et al.
Nature Communications
|
March 30, 2019
Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor
Santanu Adhikary, Deepavali Chakravarti, Christopher Terranova, et al.
Journal of Clinical Pathology
|
August 3, 2006
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer
Khawla Al-Kuraya, Hedvika Novotny, Prashant Bavi, et al.
Scientific Reports
|
January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
Seyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 21, 2011
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time
Eric A Ariazi, Heather E Cunliffe, Joan S Lewis-Wambi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2017
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Kurt W Evans, Erkan Yuca, Argun Akcakanat, et al.
Breast Cancer Research : BCR
|
March 5, 2021
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
Seyed Pairawan, Ming Zhao, Erkan Yuca, et al.
Plos One
|
June 5, 2012
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
Zsuzsanna Varga, Joachim Diebold, Corina Dommann-Scherrer, et al.
Journal for Immunotherapy of Cancer
|
September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
JCO Precision Oncology
|
July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast Cancer
Funda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
Page
of 5